You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMepivacaine
Accession NumberDB00961  (APRD01094)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA local anesthetic that is chemically related to bupivacaine but pharmacologically related to lidocaine. It is indicated for infiltration, nerve block, and epidural anesthesia. Mepivacaine is effective topically only in large doses and therefore should not be used by this route. (From AMA Drug Evaluations, 1994, p168)
Structure
Thumb
Synonyms
(+-)-1-Methyl-2',6'-pipecoloxylidide
1-methyl-2',6'-pipecoloxylidide
Carbocaine
DL-Mepivacaine
Mepivacaina
Mepivacainum
N-(2,6-Dimethylphenyl)-1-methyl-2-piperidinecarboxamide
N-(2,6-Dimethylphenyl)-1-methylpiperidine-2-carboxamide
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
3% Polocaine DentalLiquid30 mgInfiltrationDentsply Canada Limited2009-10-19Not applicableCanada
CarbocaineInjection, solution10 mg/mLEpidural; InfiltrationHospira, Inc.1960-03-15Not applicableUs
CarbocaineInjection, solution20 mg/mLInfiltrationHospira, Inc.1960-03-15Not applicableUs
CarbocaineInjection, solution10 mg/mLInfiltrationHospira, Inc.1960-03-15Not applicableUs
CarbocaineInjection, solution15 mg/mLEpidural; InfiltrationHospira, Inc.1960-03-15Not applicableUs
CarbocaineInjection, solution20 mg/mLEpidural; InfiltrationHospira, Inc.1960-03-15Not applicableUs
Carbocaine Liq 2%Liquid20 mgEpidural; IntracaudalSanofi Canada, Inc.1959-12-312001-08-10Canada
Carbocaine 1%Solution1 %Epidural; IntracaudalHospira Healthcare Corporation2001-06-01Not applicableCanada
Carbocaine 1%Solution1 %InfiltrationHospira Healthcare Corporation2001-07-15Not applicableCanada
Carbocaine 2%Solution20 mgEpidural; IntracaudalHospira Healthcare Corporation2001-07-15Not applicableCanada
Carbocaine 3%Solution30 mgInfiltrationKodak Canada Inc.1993-12-312008-07-14Canada
Carbocaine 3%Solution30 mgInfiltrationCarestream Health Canada Company2005-11-21Not applicableCanada
Carbocaine Inj Liq 10mg/mlLiquid10 mgEpidural; IntracaudalSterling Winthrop Inc.1992-12-311996-09-10Canada
Carbocaine Inj Liq 20mg/mlLiquid20 mgIntraspinalSterling Winthrop Inc.1992-12-311996-09-10Canada
Carbocaine Liq 1%Liquid1 %InfiltrationSanofi Canada, Inc.1959-12-312001-08-10Canada
Carbocaine Liq 1%Liquid1 %Epidural; IntracaudalSanofi Canada, Inc.1959-12-312001-08-10Canada
Isocaine HCl Inj 3%Solution30 mgSubcutaneousNovocol Pharmaceutical Of Canada Inc1977-12-31Not applicableCanada
Mepivicaine Hydrochloride Injection, USP 3%Solution30 mgInfiltrationDentsply Canada Limited1989-12-312012-07-19Canada
Scandonest 3% Plain InjLiquid30 mgInfiltrationSeptodont1980-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CarbocaineInjection, solution30 mg/mLSubcutaneousCaresteam Health, Inc.2011-01-01Not applicableUs
Iq Dental MepivacaineInjection, solution30 mg/mLSubcutaneousIq Dental2012-08-15Not applicableUs
IsocaineInjection, solution30 mg/mLSubcutaneousNovocol Pharmaceutical of Canada, Inc.2010-08-20Not applicableUs
MepivacaineInjection, solution30 mg/mLSubcutaneousDarby Dental Supply, LLC2011-01-14Not applicableUs
MepivacaineInjection, solution30 mg/mLSubcutaneousBenco Dental2011-01-01Not applicableUs
MepivacaineInjection, solution30 mg/mLSubcutaneousPatterson Dental Supply, Inc.2011-01-01Not applicableUs
MepivacaineInjection, solution30 mg/mLSubcutaneousNovocol Pharmaceutical of Canada, Inc.2013-07-31Not applicableUs
MepivacaineInjection, solution30 mg/mLSubcutaneousNDC, Inc.2015-04-10Not applicableUs
Mepivacaine HydrochlorideInjection, solution30 mg/mLDental; InfiltrationHospira, Inc.2008-04-28Not applicableUs
Mepivacaine HydrochlorideInjection, solution30 mg/mLSubcutaneousSafco Dental Supply Co.2011-01-01Not applicableUs
Mepivacaine HydrochlorideInjection, solution30 mg/mLSubcutaneousHenry Schein Inc.2011-01-01Not applicableUs
Pearson MepivacaineInjection, solution30 mg/mLSubcutaneousPearson Dental2012-05-15Not applicableUs
PolocaineInjection, solution20 mg/mLInfiltrationAPP Pharmaceuticals, LLC2009-07-20Not applicableUs
PolocaineInjection, solution10 mg/mLInfiltrationAPP Pharmaceuticals, LLC2009-07-20Not applicableUs
PolocaineInjection, solution30 mg/mLSubcutaneousDentsply Pharmaceutical1984-10-10Not applicableUs
Polocaine-mpfInjection, solution15 mg/mLEpidural; InfiltrationAPP Pharmaceuticals, LLC2009-07-21Not applicableUs
Polocaine-mpfInjection, solution20 mg/mLEpidural; InfiltrationAPP Pharmaceuticals, LLC2009-07-21Not applicableUs
Polocaine-mpfInjection, solution10 mg/mLEpidural; InfiltrationAPP Pharmaceuticals, LLC2009-07-20Not applicableUs
Scandonest PlainInjection, solution30 mg/mLSubcutaneousNovocol Pharmaceutical of Canada, Inc.2013-06-26Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ScandicaineNot Available
Brand mixtures
NameLabellerIngredients
2% Polocaine Dental With Levonordefrin 1:20,000Dentsply Canada Limited
Carbocaine 2% With Neo-cobefrinCarestream Health Canada Company
Carbocaine With Neo-cobefrinCaresteam Health, Inc.
Isocaine HCl Inj 2%Novocol Pharmaceutical Of Canada Inc
Mepivacaine Hydrochloride and LevonordefrinDarby Dental Supply, LLC
Mepivacaine Hydrochloride With LevonordefrinHenry Schein Inc.
Mepivacaine With LevonordefrinPatterson Dental Supply, Inc.
Scandonest 2% Special InjSeptodont
Scandonest 2% With LevonordefrinNovocol Pharmaceutical Of Canada Inc
Scandonest LNovocol Pharmaceutical Of Canada, Inc
Salts
Name/CASStructureProperties
Mepivacaine Hydrochloride
1722-62-9
Thumb
  • InChI Key: RETIMRUQNCDCQB-UHFFFAOYNA-N
  • Monoisotopic Mass: 282.149891075
  • Average Mass: 282.809
DBSALT000478
Categories
UNIIB6E06QE59J
CAS number96-88-8
WeightAverage: 246.348
Monoisotopic: 246.173213336
Chemical FormulaC15H22N2O
InChI KeyINWLQCZOYSRPNW-UHFFFAOYSA-N
InChI
InChI=1S/C15H22N2O/c1-11-7-6-8-12(2)14(11)16-15(18)13-9-4-5-10-17(13)3/h6-8,13H,4-5,9-10H2,1-3H3,(H,16,18)
IUPAC Name
N-(2,6-dimethylphenyl)-1-methylpiperidine-2-carboxamide
SMILES
CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C
Pharmacology
IndicationFor production of local or regional analgesia and anesthesia by local infiltration, peripheral nerve block techniques, and central neural techniques including epidural and caudal blocks.
Structured Indications Not Available
PharmacodynamicsMepivicaine is a local anesthetic of the amide type. Mepivicaine as a reasonably rapid onset and medium duration and is known by the proprietary names as Carbocaine and Polocaine. Mepivicaine is used in local infiltration and regional anesthesia. Systemic absorption of local anesthetics produces effects on the cardiovascular and central nervous systems. At blood concentrations achieved with normal therapeutic doses, changes in cardiac conduction, excitability, refractoriness, contractility, and peripheral vascular resistance are minimal.
Mechanism of actionLocal anesthetics block the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of affected nerve fibers. Clinically, the order of loss of nerve function is as follows: pain, temperature, touch, proprioception, and skeletal muscle tone.
TargetKindPharmacological actionActionsOrganismUniProt ID
Sodium channel protein type 10 subunit alphaProteinyes
inhibitor
HumanQ9Y5Y9 details
Related Articles
AbsorptionAbsorbed locally. The rate of systemic absorption of local anesthetics is dependent upon the total dose and concentration of drug administered, the route of administration, the vascularity of the administration site, and the presence or absence of epinephrine in the anesthetic solution.
Volume of distributionNot Available
Protein bindingMepivacaine is approximately 75% bound to plasma proteins. Generally, the lower the plasma concentration of drug, the higher the percentage of drug bound to plasma.
Metabolism

Rapidly metabolized, with only a small percentage of the anesthetic (5 percent to 10 percent) being excreted unchanged in the urine. The liver is the principal site of metabolism, with over 50% of the administered dose being excreted into the bile as metabolites.

Route of eliminationIt is rapidly metabolized, with only a small percentage of the anesthetic (5 percent to 10 percent) being excreted unchanged in the urine.The liver is the principal site of metabolism, with over 50% of the administered dose being excreted into the bile as metabolites.
Half lifeThe half-life of mepivacaine in adults is 1.9 to 3.2 hours and in neonates 8.7 to 9 hours.
ClearanceNot Available
ToxicityThe mean seizure dosage of mepivacaine in rhesus monkeys was found to be 18.8 mg/kg with mean arterial plasma concentration of 24.4 µg/mL. The intravenous and subcutaneous LD 50 in mice is 23 mg/kg to 35 mg/kg and 280 mg/kg respectively.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Mepivacaine Action PathwayDrug actionSMP00399
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when Mepivacaine is combined with 7-Nitroindazole.Experimental
AcebutololThe serum concentration of Mepivacaine can be increased when it is combined with Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Aceprometazine.Approved
adipiplonThe risk or severity of adverse effects can be increased when Mepivacaine is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Mepivacaine.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Mepivacaine.Approved, Illicit, Investigational
AlprenololThe serum concentration of Mepivacaine can be increased when it is combined with Alprenolol.Approved, Withdrawn
AmisulprideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Amperozide.Experimental
Aop200704The serum concentration of Mepivacaine can be increased when it is combined with Aop200704.Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Aripiprazole.Approved, Investigational
ArotinololThe serum concentration of Mepivacaine can be increased when it is combined with Arotinolol.Approved
ArticaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Asenapine.Approved
AtenololThe serum concentration of Mepivacaine can be increased when it is combined with Atenolol.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Azaperone.Vet Approved
AzelastineMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Barbital.Illicit
BefunololThe serum concentration of Mepivacaine can be increased when it is combined with Befunolol.Experimental
BenperidolThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Benzocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Benzyl alcohol.Approved
BetaxololThe serum concentration of Mepivacaine can be increased when it is combined with Betaxolol.Approved
BevantololThe serum concentration of Mepivacaine can be increased when it is combined with Bevantolol.Approved
BisoprololThe serum concentration of Mepivacaine can be increased when it is combined with Bisoprolol.Approved
BopindololThe serum concentration of Mepivacaine can be increased when it is combined with Bopindolol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Bromazepam.Approved, Illicit
BrompheniramineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Brotizolam.Approved, Withdrawn
BucindololThe serum concentration of Mepivacaine can be increased when it is combined with Bucindolol.Investigational
BufuralolThe serum concentration of Mepivacaine can be increased when it is combined with Bufuralol.Experimental, Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Mepivacaine.Approved, Investigational
BupranololThe serum concentration of Mepivacaine can be increased when it is combined with Bupranolol.Approved
BuprenorphineMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Mepivacaine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Mepivacaine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Mepivacaine.Approved, Illicit, Vet Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Mepivacaine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Carisoprodol.Approved
CarteololThe serum concentration of Mepivacaine can be increased when it is combined with Carteolol.Approved
CarvedilolThe serum concentration of Mepivacaine can be increased when it is combined with Carvedilol.Approved, Investigational
CeliprololThe serum concentration of Mepivacaine can be increased when it is combined with Celiprolol.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Mepivacaine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Mepivacaine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Mepivacaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Mepivacaine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Mepivacaine.Approved, Illicit
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Mepivacaine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Mepivacaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Mepivacaine.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Mepivacaine.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Mepivacaine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dapoxetine.Investigational
deramciclaneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Mepivacaine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Mepivacaine.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Mepivacaine.Approved, Illicit, Vet Approved
DifenoxinThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Diphenoxylate.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Mepivacaine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Mepivacaine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Mepivacaine is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Efavirenz.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Mepivacaine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Entacapone.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Escitalopram.Approved, Investigational
EsmololThe serum concentration of Mepivacaine can be increased when it is combined with Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Mepivacaine.Approved
EthanolMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Mepivacaine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Mepivacaine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Mepivacaine.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Mepivacaine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Mepivacaine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Mepivacaine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fluticasone Propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Mepivacaine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fospropofol.Approved, Illicit
GabapentinThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Mepivacaine is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Mepivacaine.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Mepivacaine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Hexobarbital.Approved
HyaluronidaseThe risk or severity of adverse effects can be increased when Hyaluronidase is combined with Mepivacaine.Approved, Investigational
HydrocodoneMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Mepivacaine.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Indalpine.Investigational, Withdrawn
IndenololThe serum concentration of Mepivacaine can be increased when it is combined with Indenolol.Withdrawn
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Mepivacaine.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ketobemidone.Approved
LabetalolThe serum concentration of Mepivacaine can be increased when it is combined with Labetalol.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Levetiracetam.Approved, Investigational
LevobunololThe serum concentration of Mepivacaine can be increased when it is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Mepivacaine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Mepivacaine.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Lofentanil.Illicit
LoratadineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Mepivacaine.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Mepivacaine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Mepivacaine is combined with Lu AA21004.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Melperone.Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Mepivacaine.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Mepivacaine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Mepivacaine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Mepivacaine.Approved
MethotrimeprazineMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Methsuximide.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Mepivacaine.Approved
MetipranololThe serum concentration of Mepivacaine can be increased when it is combined with Metipranolol.Approved
MetoprololThe serum concentration of Mepivacaine can be increased when it is combined with Metoprolol.Approved, Investigational
MetyrosineMepivacaine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Mepivacaine.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.Approved, Investigational
MirtazapineMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Mepivacaine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.Approved, Investigational
NadololThe serum concentration of Mepivacaine can be increased when it is combined with Nadolol.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Mepivacaine.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Mepivacaine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Mepivacaine.Approved
OpiumThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Opium.Approved, Illicit
OrphenadrineMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Mepivacaine.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Oxetacaine.Investigational
OxprenololThe serum concentration of Mepivacaine can be increased when it is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Mepivacaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Mepivacaine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Oxymorphone.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Paliperidone.Approved
ParaldehydeMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Paroxetine.Approved, Investigational
PenbutololThe serum concentration of Mepivacaine can be increased when it is combined with Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Mepivacaine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Mepivacaine.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.Approved
PerazineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Mepivacaine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Mepivacaine.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Phenoxyethanol.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Pimozide.Approved
PindololThe serum concentration of Mepivacaine can be increased when it is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Pomalidomide.Approved
PractololThe serum concentration of Mepivacaine can be increased when it is combined with Practolol.Approved
PramipexoleMepivacaine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Mepivacaine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Mepivacaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Mepivacaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Mepivacaine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Mepivacaine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Mepivacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Mepivacaine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Propoxycaine.Approved
PropranololThe serum concentration of Mepivacaine can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Mepivacaine is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Quetiapine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Mepivacaine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Mepivacaine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Mepivacaine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Mepivacaine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Romifidine.Vet Approved
RopiniroleMepivacaine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Mepivacaine.Approved
RotigotineMepivacaine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Mepivacaine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Mepivacaine is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Mepivacaine is combined with Sage 547.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Mepivacaine.Approved, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Sevoflurane.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.Approved
SotalolThe serum concentration of Mepivacaine can be increased when it is combined with Sotalol.Approved
StiripentolThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Mepivacaine.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Mepivacaine.Approved
SuvorexantMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tasimelteon.Approved
Technetium Tc-99m tilmanoceptMepivacaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Mepivacaine.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tetrodotoxin.Investigational
ThalidomideMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Mepivacaine.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Mepivacaine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tiapride.Investigational
TiletamineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tiletamine.Vet Approved
TimololThe serum concentration of Mepivacaine can be increased when it is combined with Timolol.Approved
TizanidineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Mepivacaine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Mepivacaine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Mepivacaine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Mepivacaine.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Mepivacaine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Mepivacaine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Mepivacaine is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Mepivacaine.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Venlafaxine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Vigabatrin.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Mepivacaine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Zolazepam.Vet Approved
ZolpidemMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

DrugSyn.org

US2799679
General ReferencesNot Available
External Links
ATC CodesN01BB53N01BB03
AHFS Codes
  • 72:00.00
PDB EntriesNot Available
FDA labelDownload (180 KB)
MSDSDownload (73.2 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9568
Blood Brain Barrier+0.9749
Caco-2 permeable+0.6836
P-glycoprotein substrateSubstrate0.7866
P-glycoprotein inhibitor IInhibitor0.6872
P-glycoprotein inhibitor IINon-inhibitor0.8665
Renal organic cation transporterNon-inhibitor0.5878
CYP450 2C9 substrateNon-substrate0.7853
CYP450 2D6 substrateSubstrate0.7423
CYP450 3A4 substrateSubstrate0.7726
CYP450 1A2 substrateNon-inhibitor0.7996
CYP450 2C9 inhibitorNon-inhibitor0.933
CYP450 2D6 inhibitorInhibitor0.6146
CYP450 2C19 inhibitorNon-inhibitor0.9387
CYP450 3A4 inhibitorNon-inhibitor0.5395
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7497
Ames testNon AMES toxic0.8252
CarcinogenicityNon-carcinogens0.9333
BiodegradationNot ready biodegradable0.939
Rat acute toxicity1.7237 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.908
hERG inhibition (predictor II)Inhibitor0.6936
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Solvay pharmaceuticals
  • Eastman kodak co
  • Hospira inc
  • Novocol pharmaceutical inc
  • Graham chemical co
  • International medication system
  • Watson laboratories inc
  • App pharmaceuticals llc
  • Dentsply pharmaceutical
  • Deproco inc
Packagers
Dosage forms
FormRouteStrength
Injection, solutionEpidural; Infiltration10 mg/mL
Injection, solutionEpidural; Infiltration15 mg/mL
Injection, solutionEpidural; Infiltration20 mg/mL
Injection, solutionInfiltration10 mg/mL
Injection, solutionInfiltration20 mg/mL
Injection, solutionSubcutaneous30 mg/mL
LiquidEpidural; Intracaudal20 mg
SolutionEpidural; Intracaudal1 %
SolutionInfiltration1 %
SolutionEpidural; Intracaudal20 mg
SolutionInfiltration30 mg
LiquidEpidural; Intracaudal10 mg
LiquidIntraspinal20 mg
LiquidEpidural; Intracaudal1 %
LiquidInfiltration1 %
Injection, solutionSubcutaneous
SolutionInfiltration
SolutionSubcutaneous30 mg
Injection, solutionDental; Infiltration30 mg/mL
LiquidInfiltration
LiquidInfiltration30 mg
Prices
Unit descriptionCostUnit
Mepivacaine hcl powder318.33USD g
Mepivacaine hcl 3% cartridge0.46USD ml
Carbocaine 1% vial0.26USD ml
Polocaine 1% vial0.25USD ml
Polocaine 2% vial0.24USD ml
Carbocaine 2% vial0.19USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point150.5 °CPhysProp
water solubility7000 mg/L (at 23 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.95HANSCH,C ET AL. (1995)
logS-1.55ADME Research, USCD
pKa7.7SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.621 mg/mLALOGPS
logP2.16ALOGPS
logP3.19ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)13.62ChemAxon
pKa (Strongest Basic)7.25ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area32.34 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity76.32 m3·mol-1ChemAxon
Polarizability28.61 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.1 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0002-9000000000-6a3d80d214452a24ab62View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentAlpha amino acid amides
Alternative Parents
Substituents
  • Alpha-amino acid amide
  • N-arylamide
  • Piperidinecarboxylic acid
  • Piperidinecarboxamide
  • 2-piperidinecarboxamide
  • Benzenoid
  • Piperidine
  • Monocyclic benzene moiety
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated sodium channel activity
Specific Function:
Tetrodotoxin-resistant channel that mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which sodium ions may pass in accordance with their electrochemical gradient. Plays a role in neuropathic pain mechanisms.
Gene Name:
SCN10A
Uniprot ID:
Q9Y5Y9
Molecular Weight:
220623.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Leffler A, Reckzeh J, Nau C: Block of sensory neuronal Na+ channels by the secreolytic ambroxol is associated with an interaction with local anesthetic binding sites. Eur J Pharmacol. 2010 Mar 25;630(1-3):19-28. doi: 10.1016/j.ejphar.2009.12.027. Epub 2010 Jan 4. [PubMed:20044988 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23